🇪🇺 Syfovre™ in European Union

EMA authorised Syfovre™ on 16 December 2024

Marketing authorisation

EMA — authorised 16 December 2024

  • Application: EMEA/H/C/005954
  • Marketing authorisation holder: Apellis Europe B.V.
  • Local brand name: Syfovre
  • Indication: Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • Status: rejected

The EMA has approved Syfovre, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Syfovre is developed by Apellis Europe B.V. and will be marketed under the local brand name Syfovre. The approval was granted on 16 December 2024, following a standard marketing authorisation application.

Read official source →

Syfovre™ in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Ophthalmology approved in European Union

Frequently asked questions

Is Syfovre™ approved in European Union?

Yes. EMA authorised it on 16 December 2024.

Who is the marketing authorisation holder for Syfovre™ in European Union?

Apellis Europe B.V. holds the EU marketing authorisation.